Seminars in Oncology
Volume 30, Issue 5 , Pages 667-676, October 2003

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen☆

  • Neil H Bander

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Neil H. Bander, MD, The New York Presbyterian Hospital-Weill Medical College of Cornell University, 525 E 68th St, New York, NY 10021, USA
    • Department of Urology, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • David M Nanus

      Affiliations

    • Department of Urology, Weill Medical College of Cornell University, New York, NY, USA
    • Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Matthew I Milowsky

      Affiliations

    • Department of Urology, Weill Medical College of Cornell University, New York, NY, USA
    • Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Lale Kostakoglu

      Affiliations

    • Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Shankar Vallabahajosula

      Affiliations

    • Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA
    • ,
  • Stanley J Goldsmith

      Affiliations

    • Department of Radiology, Weill Medical College of Cornell University, New York, NY, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Supported in part by NIH General Clinical Research Centers Program (NCRR Grant No. M01RR00047); US Department of Army (DAMD17-98-1-8594), Cancer Research Institute, Cap Cure, the David H. Koch Foundation, the Peter Sacerdote Foundation, BZL Biologics, Inc, and Millennium Pharmaceuticals, Inc. N.H.B. developed the J591 antibody used in this study. J591 and related anti-PSMAext antibody patents were assigned to the Cornell Research Foundation and subsequently licensed to BZL Biologics, Inc. N.H.B. is a paid consultant to BZL Biologics, Inc.

PII: S0093-7754(03)00358-0

doi:10.1016/S0093-7754(03)00358-0

Seminars in Oncology
Volume 30, Issue 5 , Pages 667-676, October 2003

Article Tools

* Image Usage & Resolution